13-azaprostanoic acid profile

13-Azaprostanoic acid is a synthetic analog of prostaglandin E1 (PGE1), a naturally occurring hormone-like substance. Unlike PGE1, which has a five-membered ring structure, 13-azaprostanoic acid has a nitrogen atom replacing a carbon atom in that ring. This seemingly small change has significant implications for its biological activity and makes it a valuable tool for research.

Here's why 13-azaprostanoic acid is important for research:

**1. Selective Prostaglandin Receptor Agonist:** 13-azaprostanoic acid is a selective agonist of the EP3 receptor, one of the four major subtypes of prostaglandin E receptors (EP1, EP2, EP3, and EP4). This selective action allows researchers to study the specific roles of the EP3 receptor in various physiological processes, without the confounding effects of activating other receptors.

**2. Pharmacological Studies:** 13-azaprostanoic acid has been used extensively in pharmacological studies to investigate the role of prostaglandins in various physiological processes, including:

* **Inflammation:** The EP3 receptor is known to play a role in inflammation, and 13-azaprostanoic acid has been used to study the effects of EP3 receptor activation on inflammatory responses.
* **Cardiovascular System:** PGE1 and its analogs, including 13-azaprostanoic acid, have shown potential therapeutic benefits in cardiovascular diseases. Studies have explored their use in conditions like hypertension, myocardial infarction, and heart failure.
* **Gastrointestinal System:** The EP3 receptor is also implicated in regulating gastrointestinal function. 13-azaprostanoic acid has been used to investigate the role of EP3 receptor activation in gastrointestinal motility, secretion, and inflammation.
* **Other Systems:** 13-azaprostanoic acid has been used to study the role of the EP3 receptor in other systems, including the central nervous system, respiratory system, and reproductive system.

**3. Development of New Drugs:** The selective activation of the EP3 receptor by 13-azaprostanoic acid has sparked interest in developing new drugs that target this receptor for therapeutic purposes. For example, compounds that selectively activate or block the EP3 receptor may have potential for treating inflammatory diseases, cardiovascular diseases, and other conditions.

**4. Understanding Disease Mechanisms:** By studying the effects of 13-azaprostanoic acid, researchers can gain a deeper understanding of the mechanisms by which prostaglandins and their receptors contribute to various physiological processes and diseases.

**Limitations:**

While 13-azaprostanoic acid has been a valuable tool in research, it does have some limitations:

* **Metabolic Stability:** Like many other prostaglandin analogs, 13-azaprostanoic acid has limited metabolic stability, meaning it can be rapidly broken down in the body. This can limit its in vivo efficacy.
* **Pharmacokinetic Properties:** The pharmacokinetic properties of 13-azaprostanoic acid, such as absorption, distribution, metabolism, and excretion, can vary depending on the route of administration and the specific experimental conditions.

Overall, 13-azaprostanoic acid remains an important tool for research, providing insights into the role of the EP3 receptor in various physiological processes and disease mechanisms. Its selectivity and potential therapeutic value continue to drive investigations aimed at developing novel drugs that target the EP3 receptor for clinical applications.

13-azaprostanoic acid: RN given refers to (1S-trans)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	123640
CHEMBL ID	9811
SCHEMBL ID	7719993
MeSH ID	M0078836

Synonym
CBIOL_001997
BIO1_000772
BIO1_001261
BIO1_000283
NCGC00161297-01
13-azaprostanoic acid
71629-07-7
CHEMBL9811
(+/-)13-azaprostanoic acid
BML1-G10
7-[(1s,2s)-2-(heptylamino)cyclopentyl]heptanoic acid
cyclopentaneheptanoic acid, 2-(heptylamino)-, (1s-trans)-
DTXSID80221872
SCHEMBL7719993
13-apa
(+-)-13-azaprostanoic acid
7-((1s,2s)-2-(heptylamino)cyclopentyl)heptanoic acid

Excerpt	Relevance	Reference
" Exposure to 13-azaprostanoic acid (13-APA), 5 X 10(-5) M and 2 X 10(-4) M, for 20 min caused parallel and dose-related shifts to the right of the dose-response curves generated by all three prostanoids without affecting the contractile responses to KCl, norepinephrine, or 5-hydroxytryptamine or relaxation induced by PGI2."	( Antagonism of prostanoid-induced vascular contraction by 13-azaprostanoic acid (13-APA). Horn, PT; Kohli, JD; LeBreton, GC; Venton, DL, )	0.75
" By pretreatment with 13-azaprostanoic acid (13-APA), a TXA2/endoperoxide receptor antagonist, the dose-response curve of BPS in the veins was shifted to the right."	( The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein. Ishikawa, M; Namiki, A, 1994)	0.6

Assay ID	Title	Year	Journal	Article
AID157026	Tested for effect of plasma containing platelets (PRP) against U-46,619 (1 uM) at 50 uM concentration	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123068	Inhibition of cyclooxygenase activity in bovine seminal vesicles assessed as arachodonic acid dependent formation of adenochrome from L-epinephrine at 500 uM	1979	Journal of medicinal chemistry, Jul, Volume: 22, Issue:7	Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID1123067	Inhibition of ADP-induced primary platelet aggregation in aspirin-treated human platelet-rich plasma at 100 uM after 2 mins by turbidometric method	1979	Journal of medicinal chemistry, Jul, Volume: 22, Issue:7	Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID1123066	Inhibition of 300 uM arachidonate-induced platelet aggregation in human platelet-rich plasma at 10 uM by turbidometric method	1979	Journal of medicinal chemistry, Jul, Volume: 22, Issue:7	Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID157032	Tested for effect of plasma containing platelets (PRP) against arachidonic acid (500 uM) at 50 uM concentration	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123071	Inhibition of cyclooxygenase activity in bovine seminal vesicles assessed as arachodonic acid dependent formation of adenochrome from L-epinephrine at concentration of one order of magnitude greater than that necessary for 100% inhibition of platelet aggr	1979	Journal of medicinal chemistry, Jul, Volume: 22, Issue:7	Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID157031	Tested for effect of plasma containing platelets (PRP) against arachidonic acid (500 uM) at 25 uM concentration	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123064	Inhibition of 500 uM arachidonate-induced platelet aggregation in human platelet-rich plasma at 10 uM by turbidometric method	1979	Journal of medicinal chemistry, Jul, Volume: 22, Issue:7	Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID157025	Tested for effect of plasma containing platelets (PRP) against U-46,619 (1 uM) at 25 uM concentration	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123065	Inhibition of 400 uM arachidonate-induced platelet aggregation in human platelet-rich plasma at 10 uM by turbidometric method	1979	Journal of medicinal chemistry, Jul, Volume: 22, Issue:7	Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	34 (91.89)	18.7374
1990's	2 (5.41)	18.2507
2000's	1 (2.70)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.38%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	41 (97.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	1.96	1	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
5,8,11,14-eicosatetraynoic acid 5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a).	1.96	1	long-chain fatty acid
theophylline [no description available]	1.96	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	3.22	6	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	1.96	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	3.21	6	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	3.47	8	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
hydrazine diamine : Any polyamine that contains two amino groups.	2.37	2	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	1.97	1	pseudohalide anion	mitochondrial respiratory-chain inhibitor
sulotroban sulotroban: thromboxane receptor antagonist	2.37	2
dazoxiben dazoxiben: RN given refers to parent cpd	2.37	2
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	1.96	1
tretoquinol Tretoquinol: An adrenergic beta-agonist used as a bronchodilator agent in asthma therapy.	1.97	1	isoquinolines
masoprocol Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.	1.96	1	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
1-benzylimidazole 1-benzylimidazole: inhibits human thromboxane synthetase	3.06	1
fpl 55712 FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors	1.96	1	aromatic ketone
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	2.37	2	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
thromboxanes thromboxane : A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.	3.91	13
l 636499 [no description available]	1.96	1
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	1.96	1	amino acid zwitterion; angiotensin II	human metabolite
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	1.96	1	divalent inorganic anion; phosphite ion
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	1.96	1
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	4.85	11	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
prostaglandin h2 Prostaglandin H2: A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins.	8.21	6	olefinic compound; oxylipin; prostaglandins H; secondary alcohol	mouse metabolite
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.37	2	prostaglandins D	human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.96	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.66	3	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	1.96	1	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
thromboxane a2 Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.	5.31	18	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
alprostadil [no description available]	1.96	1	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	3.06	5	thromboxanes B	human metabolite; mouse metabolite
sq 29548 SQ 29548: SQ-26538 is the ((1S-1alpha,2beta(5Z),3beta(1E,3R*),4alpha))-isomer; thromboxane A2 antagonist; thromboxane receptor antagonist	2.37	2
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)	3.35	7
beraprost beraprost: stable prostacyclin analog; structure given in first source. beraprost : An organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia.	1.98	1	enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	1.96	1	benzoxazole
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.37	2
n 0164 N 0164: RN given refers to Na salt; structure	1.96	1
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	2.37	2
sta 2 STA 2: thromboxane A2 agonist; structure given in first source	2.66	3

Condition	Relationship Strength	Studies
Blood Clot [description not available]	1.96	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	1.96	1
Phlegmasia Alba Dolens Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.	2.88	1
Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS).	2.88	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.36	2
Pulmonary Hypertension [description not available]	1.96	1
Edema, Pulmonary [description not available]	1.96	1
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	1.96	1
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	1.96	1
Coronary Heart Disease [description not available]	1.96	1
Death, Sudden The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.	1.96	1
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	1.96	1
Endotoxin Shock [description not available]	1.95	1
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	1.95	1
Arterial Obstructive Diseases [description not available]	1.96	1
Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.	1.96	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.96	1

13-azaprostanoic acid

Description

Cross-References

Synonyms (17)

Research Excerpts

Dosage Studied

Bioassays (10)

Research

Studies (37)

Market Indicators

Research Demand Index: 10.51

Study Types